Lifecore Biomedical (NASDAQ:LFCR) Releases Earnings Results, Beats Estimates By $0.01 EPS

Lifecore Biomedical (NASDAQ:LFCR) posted its earnings results on Thursday. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01, Zacks reports. The firm had revenue of $31.11 million during the quarter, compared to analyst estimates of $26.68 million. Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. Lifecore Biomedical updated its FY 2026 guidance to EPS.

Lifecore Biomedical Stock Down 2.2%

LFCR traded down $0.15 on Thursday, hitting $6.62. The company had a trading volume of 96,412 shares, compared to its average volume of 205,059. The stock has a fifty day moving average price of $7.15 and a 200-day moving average price of $7.19. Lifecore Biomedical has a 12-month low of $4.76 and a 12-month high of $8.85. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.77 and a current ratio of 2.84. The stock has a market capitalization of $248.02 million, a price-to-earnings ratio of -5.05 and a beta of 0.61.

Analysts Set New Price Targets

LFCR has been the subject of a number of analyst reports. Wall Street Zen upgraded Lifecore Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. KeyCorp started coverage on Lifecore Biomedical in a research report on Wednesday, September 3rd. They set a “sector weight” rating for the company. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Lifecore Biomedical has an average rating of “Hold” and an average target price of $8.00.

Hedge Funds Weigh In On Lifecore Biomedical

Several institutional investors and hedge funds have recently added to or reduced their stakes in LFCR. State of Wyoming purchased a new position in Lifecore Biomedical in the second quarter valued at about $69,000. The Manufacturers Life Insurance Company purchased a new position in Lifecore Biomedical in the second quarter valued at about $88,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock valued at $104,000 after purchasing an additional 1,886 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Lifecore Biomedical by 54.0% during the second quarter. Rhumbline Advisers now owns 38,091 shares of the company’s stock worth $309,000 after acquiring an additional 13,361 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Lifecore Biomedical by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 87,998 shares of the company’s stock worth $620,000 after acquiring an additional 12,647 shares during the last quarter. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.